Patents by Inventor Gerhard Sperl

Gerhard Sperl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use
    Patent number: 10301324
    Abstract: The disclosure is directed to compounds and compositions that inhibit Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase and methods of their use.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: May 28, 2019
    Assignee: Atrin Pharmaceuticals LLC
    Inventors: Henry Joseph Breslin, Oren Gilad, Gerhard Sperl, Eric J. Brown, Laura Butler
  • Ataxia Telengiectasia And RAD3-Related (ATR) Inhibitors And Methods Of Their Use
    Publication number: 20170291911
    Abstract: The disclosure is directed to compounds and compositions that inhibit Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase and methods of their use.
    Type: Application
    Filed: April 12, 2017
    Publication date: October 12, 2017
    Inventors: Henry Joseph Breslin, Oren Gilad, Gerhard Sperl, Eric J. Brown, Laura Butler
  • SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF
    Publication number: 20080096903
    Abstract: Sulfamoyl-containing compounds are disclosed, having utility as inhibitors of disease-related targets, such as Heat Shock Protein 90 (HSP90), and which are useful for treating disorders, e.g., proliferative disorders, including HSP90-mediated disorders. Methods for preparing and using the disclosed compounds are also described.
    Type: Application
    Filed: October 19, 2007
    Publication date: April 24, 2008
    Applicant: Wyeth
    Inventors: Jianxin Chen, Gerhard Sperl, Vincent Gullo, Lalitha Sista, Dallas Hughes, Yucai Peng, William Pierceall, Andrew Weiskopf, Jeremy Levin, Russell Dushin, Mercy Otteng
  • [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
    Patent number: 6486158
    Abstract: [4,5]-Fused-3,6 disubstituted-pydidazines of Formula I are useful for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasia: wherein Y1 and Y2 are independently selected from the group consisting of (CH2)n,—C(X)—NH—,—(CH2)n—C(X)—O—, and X is O or S; R1 is selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, and substituted or unsubstituted phenyl, pyridinyl, and the like; R2 is selected from the group consisting of substituted or unsubstituted phenyl, benzyl, pyridinyl, and the like; “A” is a benzene ring fused with the pyridazine ring; and R3 is independently selected in each instance form the group consisting of halogen, lower alkyl, and the like.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: November 26, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Xiaojing Wang, Gerhard Sperl, Paul Gross, Rifat Pamukcu, Gary A. Piazza
  • 1,3,6,-Trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia
    Patent number: 6455703
    Abstract: 1,3,6-Trihydro-6-Aza-3-Oxapentalen-2-One Derivatives which have the following formula: wherein R1, R2, R3, R4, R5, Y, X, m, and n are as defined in the specification.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: September 24, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Rifat Pamukcu
  • Method for treating neoplasia by exposure to N,N?-substituted benzimidazol-2-ones
    Patent number: 6420410
    Abstract: A method for inhibiting neoplastic cells and related conditions by exposing them to N,N′-substituted benzimidazol-2-ones.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: July 16, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Ulrich Ixkes, Rifat Pamukcu, Gary A. Piazza
  • Method of inhibiting neoplastic cells with benzimidazole derivatives
    Publication number: 20020082280
    Abstract: A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to benzimidazole derivatives.
    Type: Application
    Filed: November 5, 2001
    Publication date: June 27, 2002
    Inventors: Gerhard Sperl, Rifat Pamukcu, Ulrich Ixkes, Gary A. Piazza
  • Substituted benzylidene indenyl formamides, acetamides and propionamides
    Patent number: 6403831
    Abstract: Substituted benzylidene indenyl formamides, acetamides and propionamides are useful in the treatment of precancerous lesions and neoplasms.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: June 11, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Paul Gross, Klaus Brendel, Rifat Pamukcu, Gary A. Piazza
  • 1,3-disubstituted indolin-2-ones for neoplasia
    Publication number: 20020028936
    Abstract: 1,3-Disubstituted Indolin-2-Ones compounds are useful in the treatment of neoplasia.
    Type: Application
    Filed: September 28, 2001
    Publication date: March 7, 2002
    Inventors: Gerhard Sperl, Xiaojing Wang, Gary A. Piazza, Rifat Pamukcu
  • Method of inhibiting neoplastic cells with benzimidazole derivatives
    Patent number: 6348032
    Abstract: A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to benzimidazole derivatives.
    Type: Grant
    Filed: November 23, 1998
    Date of Patent: February 19, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Rifat Pamukcu, Ulrich Ixkes, Gary A. Piazza
  • 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia
    Publication number: 20010051651
    Abstract: 1,3,6-Trihydro-6-Aza-3-Oxapentalen-2-One Derivatives for inhibiting neoplastic conditions.
    Type: Application
    Filed: December 6, 2000
    Publication date: December 13, 2001
    Inventors: Gerhard Sperl, Rifat Pamukcu
  • Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
    Patent number: 6300346
    Abstract: Indenyl hydroxamic acids, (hydroxy) ureas and urethanes are useful in the treatment of precancerous lesions and neoplasms.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: October 9, 2001
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Paul Gross, Klaus Brendel, Rifat Pamukcu, Gary A. Piazza
  • Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
    Patent number: 6211177
    Abstract: A method for inhibiting neoplasia, particularly cancerous and precancerous lesions, by exposing the affected cells to substituted 2-aryl-benzimidazoles.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: April 3, 2001
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Ulrich Ixkes, Rifat Pamukcu, Gary A. Piazza
  • [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
    Patent number: 6180629
    Abstract: [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen-containing substituents in position one are useful for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasia, including precancerous and cancerous lesions.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: January 30, 2001
    Assignee: Cell Pathways, Inc.
    Inventors: Xiaojing Wang, Gerhard Sperl, Paul Gross, Rifat Pamukcu, Gary A. Piazza
  • 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia
    Patent number: 6160003
    Abstract: 1,3,6-Trihydro-6-Aza-3-Oxapentalen-2-One Derivatives of Formula I are useful for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasia: ##STR1## Wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, lower alkyl, and benzyl,R.sub.3 and R.sub.4 are selected from the group consisting of substituted or unsubstituted phenyl, and the like,R.sub.5 is selected from the group consisting of hydrogen, lower alkyl, and the like,Y is selected from the group consisting of CH.sub.2, C.dbd.O, CH--OH; m is an integer from 0-3; X is selected from the group consisting of CH.sub.2, C.dbd.O, CH--OH, and SO.sub.2 ; and n is an integer from 0-2.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: December 12, 2000
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Rifat Pamukcu
  • Substituted methoxy benzylidene indenyl acetic and propionic acids for treating patients with precancerous lesions
    Patent number: 6121321
    Abstract: Substituted methoxy benzylidene indenyl compounds are useful in the treatment of precancerous lesions and neoplasms.
    Type: Grant
    Filed: June 13, 1996
    Date of Patent: September 19, 2000
    Assignees: Cell Pathways, Inc., University of Arizona
    Inventors: Gerhard Sperl, Paul Gross, Klaus Brendel, Gary A. Piazza, Rifat Pamukcu
  • Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
    Patent number: 6071934
    Abstract: Indenyl hydroxamic acids, (hydroxy) ureas and urethanes are useful in the treatment of precancerous lesions and neoplasms.
    Type: Grant
    Filed: March 25, 1997
    Date of Patent: June 6, 2000
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Paul Gross, Rifat Pamukcu, Klaus Brendel, Gary A. Piazza
  • Substituted benzylidene indenyl formamides, acetamides and propionamides
    Patent number: 6063818
    Abstract: Substituted benzylidene indenyl formamides, acetamides and propionamides are useful in the treatment of precancerous lesions and neoplasms.
    Type: Grant
    Filed: June 3, 1997
    Date of Patent: May 16, 2000
    Assignee: Cell Pathways Inc.
    Inventors: Gerhard Sperl, Paul Gross, Klaus Brendel, Rifat Pamukcu, Gary A. Piazza
  • Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia
    Patent number: 6028116
    Abstract: Substituted condensation products of 1H-indenylhydroxyalkanes with aldehydes are useful for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasia, including precancerous and cancerous lesions.
    Type: Grant
    Filed: April 3, 1998
    Date of Patent: February 22, 2000
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Paul Gross, Klaus Brendel, Gary Piazza, Rifat Pamukcu
  • Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
    Patent number: 6020379
    Abstract: In position 7 substituted indenyl-3-acetic acid derivatives and pharmaceutically acceptable salts and amides thereof have anti-neoplastic activity.
    Type: Grant
    Filed: February 19, 1999
    Date of Patent: February 1, 2000
    Assignee: Cell Pathways, Inc.
    Inventor: Gerhard Sperl